Flag of the European Union EU Clinical Trials Register Help

Clinical trials for B Scan

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    1,454 result(s) found for: B Scan. Displaying page 1 of 73.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-000940-17 Sponsor Protocol Number: 64Cu Start Date*: 2018-05-07
    Sponsor Name:
    Full Title: Phase IIa clinical study of 64 CuCl2: efficacy and safety of a new tracer for urologic tumors
    Medical condition: Genitourinary tract tumors in male patients
    Disease:
    Population Age: Elderly Gender: Male
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-001433-17 Sponsor Protocol Number: Hx-CD20-405 Start Date*: 2006-06-30
    Sponsor Name:GlaxoSmithKline Research & Development Limited
    Full Title: A single-arm, international, multi-center trial of HuMax-CD20, a fully human monoclonal anti-CD20 antibody, in patients with Follicular Lymphoma who are refractory to rituximab as monotherapy or in...
    Medical condition: Non-Hodgkin Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    12.1 10003899 B-cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) DK (Prematurely Ended) DE (Completed) ES (Completed) NL (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-005542-11 Sponsor Protocol Number: 20130109 Start Date*: 2014-10-14
    Sponsor Name:Amgen Inc.
    Full Title: A Randomized, Double-Blind Study Evaluating the Efficacy, Safety and Immunogenicity of ABP 798 Compared with Rituximab in Subjects with CD20 Positive B-Cell Non-Hodgkin Lymphoma (NHL)
    Medical condition: CD20 positive B-cell non-Hodgkin lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) CZ (Completed) RO (Completed) IT (Completed) ES (Completed) FR (Completed) BG (Completed) PL (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2014-004244-35 Sponsor Protocol Number: 1/25-03-2014 Start Date*: 2015-03-05
    Sponsor Name:IRCCS Ospedale San Raffaele
    Full Title: AMYLOID LOAD IN PRODROMAL AD WITH LIMBIC-PREDOMINANT PHENOTYPE PRINCIPAL INVESTIGATOR - STUDIO DEL CARICO DI AMILOIDE IN AD PRODROMICO CON FENOTIPO LIMBICO
    Medical condition: mild cognitive impairment, Alzheimer's disease prodromal
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004848 10050727 RI scan LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000244-27 Sponsor Protocol Number: Hx-CD20-409 Start Date*: 2007-05-23
    Sponsor Name:GlaxoSmithKline Research and Development Limited
    Full Title: An open-labeled, randomized, two-dose, parallel group trial of ofatumumab, a fully human monoclonal anti-CD20 antibody, in combination with CHOP, in patients with previously untreated Follicular L...
    Medical condition: Non-Hodgkin Follicular Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003899 B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) DK (Completed) SE (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-012944-17 Sponsor Protocol Number: 2009mwo01 Start Date*: 2009-07-31
    Sponsor Name:VUMC
    Full Title: Effect of a single dose of 14.8 MBq/kg (0.4 mCi/kg) 90Y-ibritumomab tiuxetan (“Zevalin”) following first-line R-CVP therapy in patients with follicular lymphoma on conversion rate assessed by FDG-P...
    Medical condition: follicular B cell NHL
    Disease: Version SOC Term Classification Code Term Level
    9.1 10024914 Low grade lymphoma LLT
    9.1 10003899 B-cell lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-000175-13 Sponsor Protocol Number: FIL_PanAL10 Start Date*: 2011-04-26
    Sponsor Name:FONDAZIONE ITALIANA LINFOMI ONLUS
    Full Title: A phase II study of oral Panobinostat in adult patients with relapsed/refractory diffuse large B-cell lymphoma after high-dose chemotherapy with autologous stem cell transfusion (ASCT) or in adult...
    Medical condition: Patient has a history of DLBCL according to the WHO classification. with progressive disease after receiving at least CHOP-R or CHOP-R like first line regimen and is not considered eligible for in...
    Disease: Version SOC Term Classification Code Term Level
    13.1 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000132-41 Sponsor Protocol Number: B3281006 Start Date*: 2014-10-10
    Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017
    Full Title: A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY OF PF-05280586 VERSUS RITUXIMAB FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH CD20-POSITIVE, LOW TUMOR BURDEN, FOLLICULAR LYMPHOMA
    Medical condition: low tumor burden follicular lymphoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) DE (Completed) ES (Completed) IT (Completed) PT (Completed) AT (Completed) HR (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2021-005725-24 Sponsor Protocol Number: M22-132 Start Date*: 2022-04-25
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: Phase 1b/2, Open-Label Study to Evaluate Safety and Tolerability of Epcoritamab in Combination with Anti-Neoplastic Agents in Subjects with Non-Hodgkin Lymphoma
    Medical condition: B-cell Non-Hodgkin's lymphoma, diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10003903 B-cell lymphoma refractory PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012822 Diffuse large B-cell lymphoma refractory PT
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NL (Trial now transitioned) DK (Trial now transitioned) HU (Ongoing) DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-001127-40 Sponsor Protocol Number: GO40554 Start Date*: 2019-05-10
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE I/II TRIAL OF MOSUNETUZUMAB (BTCT4465A) AS CONSOLIDATION THERAPY IN PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA FOLLOWING FIRST-LINE IMMUNOCHEMOTHERAPY AND AS THERAPY IN PATIENTS WITH PREVI...
    Medical condition: B-cell non-Hodgkin lymphoma (NHL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted)
    Trial results: (No results available)
    EudraCT Number: 2016-001966-27 Sponsor Protocol Number: AGB002 Start Date*: 2016-09-07
    Sponsor Name:Archigen Biotech Limited
    Full Title: A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients w...
    Medical condition: Low Tumor Burden Follicular Lymphoma (LTBFL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) GB (Completed) CZ (Completed) BG (Completed) FR (Completed) LV (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2020-003117-35 Sponsor Protocol Number: EFC16723 Start Date*: 2021-03-17
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A randomized, double-blind, placebo-controlled, 2-part study to evaluate the efficacy and safety of dupilumab in patients with uncontrolled, chronic rhinosinusitis without nasal polyposis (CRSsNP)
    Medical condition: Chronic rhinosinusitis without nasal polyposis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10009137 Chronic sinusitis PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) PT (Completed) SE (Completed) HU (Ongoing) PL (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2014-003418-10 Sponsor Protocol Number: IRST202.02 Start Date*: 2014-12-17
    Sponsor Name:ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI IRST - IRCCS
    Full Title: PEPTIDE RECEPTOR RADIONUCLIDE THERAPY WITH 90Y-DOTATOC IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL AND MANTLE CELL LYMPHOMAS
    Medical condition: Relapsed or refractory DLBCL (DIFFUSE LARGE B CELL LYMPHOMAS) or MCL (MANTLE CELL LYMPHOMAS)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    17.0 10005329 - Blood and lymphatic system disorders 10026798 Mantle cell lymphomas HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-005851-15 Sponsor Protocol Number: GAINED Start Date*: 2013-05-13
    Sponsor Name:LYSARC
    Full Title: A RANDOMIZED PHASE III STUDY USING A PET-DRIVEN STRATEGY AND COMPARING GA101 OR RITUXIMAB IN COMBINATION WITH A CHEMOTHERAPY DELIVERED EVERY 14 DAYS (ACVBP OR CHOP) IN DLBCL CD20+ LYMPHOMA UNTREATE...
    Medical condition: Patients with histologically proven CD20+ diffuse large B cell lymphoma (WHO Classification), Aged ≥18 years and ≤60 years, with Age adjusted International Prognostic Index (aa-IPI) equal to 1, 2 or 3
    Disease: Version SOC Term Classification Code Term Level
    18.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-002628-29 Sponsor Protocol Number: R&D6327 Start Date*: 2014-09-09
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Evaluating the effectiveness of intravenous ciclosporin on reducing reperfusion injury in patients undergoing primary percutaneous coronary intervention: a double-blind, phase II, randomised contro...
    Medical condition: Myocardial ischemia/reperfusion injury
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-004087-40 Sponsor Protocol Number: PR-CS011 Start Date*: 2008-10-06
    Sponsor Name:Prospect Therapeutics, Inc
    Full Title: A Phase 2 Study of GCS-100 in Combination with Chemo-immunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Medical condition: Relapsed or refractory diffuse large B-cell lymphoma
    Disease: Version SOC Term Classification Code Term Level
    9.1 10012822 Diffuse large B-cell lymphoma refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-006475-42 Sponsor Protocol Number: ICP-CL-00107 Start Date*: 2022-06-15
    Sponsor Name:InnoCare Pharma Inc.
    Full Title: A Phase I/II, Multicenter, Open-Label, Study of a Novel Bruton’s Tyrosine Kinase Inhibitor, Orelabrutinib, in Patients with B-Cell Malignancies
    Medical condition: B-cell malignancies, including only patients with Grades 1-3a FL, MZL, MCL, and CLL/SLL
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10025320 Lymphomas non-Hodgkin's B-cell HLGT
    Population Age: Adults Gender: Male, Female
    Trial protocol: PL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001487-19 Sponsor Protocol Number: 35/14 Start Date*: 2016-04-07
    Sponsor Name:Swiss Group For Clinical Cancer Research (SAKK)
    Full Title: Rituximab with or without Ibrutinib for untreated patients with advanced follicular lymphoma in need of therapy.
    Medical condition: Follicular Lymphoma (FL), advanced disease in need of therapy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Ongoing) DK (Prematurely Ended) SE (Ongoing) FI (Ongoing) AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015556-15 Sponsor Protocol Number: 101MS325 Start Date*: 2010-05-07
    Sponsor Name:Biogen Idec Limited
    Full Title: A Multicenter, Randomized, Rater-Blind, Parallel-Group, Active Controlled Study to Evaluate the Benefits of Switching Therapy (Glatiramer Acetate or Interferon β 1a) to Natalizumab in Subjects wit...
    Medical condition: Relapsing-Remitting Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10063399 Relapsing-remitting multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) SE (Prematurely Ended) GB (Prematurely Ended) DE (Prematurely Ended) ES (Prematurely Ended) CZ (Prematurely Ended) PT (Completed) HU (Prematurely Ended) NL (Prematurely Ended) SI (Prematurely Ended) LV (Prematurely Ended) AT (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000123-12 Sponsor Protocol Number: 2020110469 Start Date*: 2021-06-22
    Sponsor Name:Odense University Hospital
    Full Title: PRISMA-PET – Primary Staging of Prostate Cancer: A Randomized Controlled Trial Comparing 18F-PSMA-1007 PET/CT to Conventional Imaging.
    Medical condition: Newly diagnosed prostate cancer, PET/CT scan used to stage newly diagnosed prostate cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 22:09:27 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA